Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
AL

NASDAQ · ALXO

ALX Oncology Holdings Inc.

Healthcare · Biotechnology

$1.22

Up+$0.00 (+0.00%)

Updated Nov 1, 2026, 12:53 PM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
114.42M
P/E ratio
-1.13
Dividend yield
0.00%
52-week range
$0.86 – $2.41
Volume
422.2K
Avg. volume
511.22K

Price performance · ALXO

ALXO price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

ALXO closed at $1.22 after 20 trading sessions, up 0.83% for the selected period.

Last close
$1.22
Period change
+0.83%
Period low
$0.89
Period high
$1.26
Daily close
View OHLC price history
ALXO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$1.20$1.26$1.195$1.22422.2K
Oct 29, 2026$1.21$1.3399$1.12$1.221.53M
Oct 28, 2026$1.09$1.19$1.03$1.182.95M
Oct 27, 2026$1.14$1.175$1.045$1.103.22M
Oct 26, 2026$1.19$1.19$1.09$1.131.04M
Oct 23, 2026$1.17$1.23$1.10$1.17556.4K
Oct 22, 2026$1.15$1.20$1.1414$1.19572.81K
Oct 21, 2026$1.25$1.30$1.15$1.15934.51K
Oct 20, 2026$1.125$1.27$1.11$1.24871.5K
Oct 19, 2026$1.05$1.145$1.015$1.141.01M
Oct 16, 2026$1.00$1.155$0.9305$1.062.43M
Oct 15, 2026$0.911$1.02$0.8617$1.003.71M
Oct 14, 2026$0.99$0.99$0.8862$0.89472.57M
Oct 13, 2026$1.26$1.26$0.9794$0.97961M
Oct 12, 2026$1.21$1.27$1.185$1.26894.8K
Oct 9, 2026$1.16$1.29$1.1505$1.251.22M
Oct 8, 2026$1.13$1.20$1.08$1.181.81M
Oct 7, 2026$1.11$1.15$1.10$1.13764.26K
Oct 6, 2026$1.19$1.21$1.09$1.111.01M
Oct 5, 2026$1.22$1.27$1.14$1.211.79M

Latest ALXO news

The latest Smart Investors Daily articles mentioning ALXO.

Stock researchCompany · Overview

ALXO research

Overview

Company profile and research snapshot.

Company profile

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$21.38
Implied upside
—
Analysts
11
ALXO recent ratings
DateFirmRatingTarget
Mar 19, 2026Wells FargoOverweight—
Mar 10, 2026HC Wainwright & Co.Buy—
Feb 5, 2026Piper SandlerOverweight—
May 21, 2025UBSBuy—
May 9, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 28, 2026

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease Subgroup analyses support CD47 expression as a predictive biomarker ASPEN-06 clinical findings further validate Company’s biomarker-driven development strategy and reinforce its continued advancement in the ongoing Phase 2 ASPEN-09-Breast clinical trial On track fo

Yahoo · Sep 2, 2026

ALX Oncology to Present at Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences. The details of the meetings are as follows: Wells Fargo 21st Annual Healthcare Conference Format: Fireside Chat and One-on-on

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By